By Fineline Cube 
Shenzhen Beimei Pharmaceutical Co., Ltd. announced on July 22, 2025, that its drug TWYNEO (tretinoin and benzoyl peroxide cream) has received the clinical trial application acceptance notice from China’s National Medical Products Administration (NMPA). The company is actively preparing for the clinical trials.
Innovative Acne Treatment
TWYNEO is the world’s first and only topical cream combining tretinoin and benzoyl peroxide in a fixed-dose formulation. Approved by the FDA in July 2021 for treating acne vulgaris in patients aged 9 and older, it leverages patented micron-encapsulation technology to stabilize the highly reactive ingredients. This reduces skin irritation and enhances patient compliance.
Clinical Success and Recommendations
In U.S. Phase III trials, TWYNEO demonstrated over 60% reduction in inflammatory and non-inflammatory acne lesions. After a 12-week course, more than 33% of patients achieved complete or near-complete skin lesion clearance. The American Academy of Dermatology (AAD) strongly recommends TWYNEO for acne treatment in patients aged 9 and above in its 2024 updated guidelines.-Fineline Info & Tech